CoChat

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Open access

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Abstract

Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than half of patients, and treatment-associated adverse events, such as immune effector cell-associated neurotoxicity syndrome (ICANS), are a clinical challenge. We performed single-cell RNA sequencing with capture-based cell identification on autologous axicabtagene ciloleucel (axi-cel) anti-CD19 CAR T cell infusion products to identify transcriptomic features associated with efficacy and toxicity in 24 patients with LBCL. Patients who achieved a complete response by positron emission tomography/computed tomography at their 3-month follow-up had three-fold higher frequencies of CD8 T cells expressing memory signatures than patients with partial response or progressive disease. Molecular response measured by cell-free DNA sequencing at day 7 after infusion was significantly associated with clinical response (P = 0.008), and a signature of CD8 T cell exhaustion was associated (q = 2.8 × 10-149) with a poor molecular response. Furthermore, a rare cell population with monocyte-like transcriptional features was associated (P = 0.0002) with high-grade ICANS. Our results suggest that heterogeneity in the cellular and molecular features of CAR T cell infusion products contributes to variation in efficacy and toxicity after axi-cel therapy in LBCL, and that day 7 molecular response might serve as an early predictor of CAR T cell efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1061-7

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 600

Metadata

Authors
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., Wang, Y., Zhang, S., Wang, R., Chen, R., Showell, J., Ghosh, S., Patchva, S., Zhang, Q., Sun, R., Hagemeister, F., Fayad, L., Samaniego, F., Lee, H. C., Nastoupil, L. J., Fowler, N., Eric Davis, R., Westin, J., Neelapu, S. S., Wang, L., & Green, M. R.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Neelapu, Sattva S.
  • Wang, Linghua
  • Green, Michael R.
Venue
Nature Medicine
Published
2020-10-05
Volume
26
Issue
12
Pages
1878-1887
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3089967262
Cited by
600
References
57
Citations by year
2026: 77 · 2025: 109 · 2024: 115 · 2023: 130 · 2022: 98 · 2021: 67 · 2020: 3
FWCI
26.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CD19 CAR T-cell therapy, axicabtagene ciloleucel, large B-cell lymphoma, immune effector cell-associated neurotoxicity syndrome, CD8+ T cell exhaustion, memory T cells, monocyte-like cells, cell-free DNA, molecular response, single-cell transcriptomics, treatment response prediction, toxicity
MeSH terms
Cell-Free Nucleic Acids, RNA-Seq, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Lymphoma, Large B-Cell, Diffuse, CD8-Positive T-Lymphocytes, Neurotoxicity Syndromes, Single-Cell Analysis, Transcriptome, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. https://app.cochat.ai/papers/10.1038/s41591-020-1061-7
The paper
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., Wang, Y., Zhang, S., Wang, R., Chen, R., Showell, J., Ghosh, S., Patchva, S., Zhang, Q., Sun, R., . . . Green, M. R. (2020). Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine. https://doi.org/10.1038/s41591-020-1061-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.